NO20092729L - Lipasevarianter for farmasoytisk anvendelse - Google Patents

Lipasevarianter for farmasoytisk anvendelse

Info

Publication number
NO20092729L
NO20092729L NO20092729A NO20092729A NO20092729L NO 20092729 L NO20092729 L NO 20092729L NO 20092729 A NO20092729 A NO 20092729A NO 20092729 A NO20092729 A NO 20092729A NO 20092729 L NO20092729 L NO 20092729L
Authority
NO
Norway
Prior art keywords
lipases
digestive
improved
pharmaceutical use
diabetes
Prior art date
Application number
NO20092729A
Other languages
English (en)
Norwegian (no)
Inventor
Peter-Colin Gregory
Allan Svendsen
Michael Skjot
Debbie Yaver
Lars Lehmann Hylling Christensen
Signe Eskildsen Larsen
Nina Lundin
Michael Lamsa
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of NO20092729L publication Critical patent/NO20092729L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Detergent Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20092729A 2006-12-21 2009-07-20 Lipasevarianter for farmasoytisk anvendelse NO20092729L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87119606P 2006-12-21 2006-12-21
PCT/US2007/087168 WO2008079685A2 (en) 2006-12-21 2007-12-12 Lipase variants for pharmaceutical use

Publications (1)

Publication Number Publication Date
NO20092729L true NO20092729L (no) 2009-09-18

Family

ID=38043020

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092729A NO20092729L (no) 2006-12-21 2009-07-20 Lipasevarianter for farmasoytisk anvendelse

Country Status (16)

Country Link
US (3) US8273348B2 (de)
EP (6) EP2099907A2 (de)
JP (1) JP5406040B2 (de)
KR (1) KR20090101930A (de)
CN (2) CN105112386A (de)
AR (1) AR064494A1 (de)
AU (1) AU2007337150A1 (de)
BR (1) BRPI0721103A2 (de)
CA (3) CA3081308C (de)
IL (1) IL198893A0 (de)
MX (1) MX2009006597A (de)
NO (1) NO20092729L (de)
RU (1) RU2009128067A (de)
TW (1) TW200829698A (de)
WO (1) WO2008079685A2 (de)
ZA (1) ZA200903598B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0509148B8 (pt) 2004-03-22 2021-05-25 Abbott Products Gmbh composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina contendo tensoativos, seus usos e respectivos processos de fabricação
JP5140586B2 (ja) 2005-07-29 2013-02-06 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 滅菌パンクレアチン粉末の製法
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
CN105112386A (zh) * 2006-12-21 2015-12-02 诺维信公司 用于药物用途的脂肪酶变体
CA2716692A1 (en) 2008-02-29 2009-09-03 Dsm Ip Assets B.V. Lipases with high specificity towards short chain fatty acids and uses thereof
CN102112602A (zh) * 2008-02-29 2011-06-29 宝洁公司 包含脂肪酶的洗涤剂组合物
MX337307B (es) * 2008-02-29 2016-02-25 Novozymes As Variante de enzima lipolitica con estabilidad mejorada y polinucleotidos que codifican para la misma.
BR112013032861A2 (pt) 2011-07-22 2017-01-24 Novozymes North America Inc métodos para aumentar a atividade da enzima celulolítica durante a hidrólise do material celulósico, para hidrolisar um material celulósico pré-tratado, para a produção de um produto da fermentação, e para a fermentação de um material celulósico pré-tratado
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
CN110777016A (zh) * 2011-12-29 2020-02-11 诺维信公司 具有脂肪酶变体的洗涤剂组合物
MX353911B (es) * 2012-02-03 2018-02-02 Novozymes As Variantes de lipasa y polinucleotidos que las codifican.
US9909109B2 (en) 2012-04-02 2018-03-06 Novozymes A/S Lipase variants and polynucleotides encoding same
AU2013328953A1 (en) * 2012-10-12 2015-03-26 Danisco Us Inc. Compositions and methods comprising a lipolytic enzyme variant
CN105209612A (zh) 2013-05-14 2015-12-30 诺维信公司 洗涤剂组合物
EP3696264B1 (de) * 2013-07-19 2023-06-28 Danisco US Inc. Zusammensetzungen und verfahren mit einer variante eines lipolytischen enzyms
EP3221447A1 (de) * 2014-11-20 2017-09-27 Novozymes A/S Alicyclobacillus-varianten und dafür codierende polynukleotide
US10457921B2 (en) 2014-12-05 2019-10-29 Novozymes A/S Lipase variants and polynucleotides encoding same
WO2016091870A1 (en) * 2014-12-09 2016-06-16 Novozymes A/S Lipase variants and polynucleotides encoding same
US20180355404A1 (en) 2015-04-07 2018-12-13 Novozymes A/S Methods for selecting enzymes having lipase activity
CN107995922B (zh) * 2015-07-03 2021-12-28 诺维信公司 在亚硫酸盐的存在下具有改进的稳定性的洗涤剂组合物
CN110462037A (zh) * 2017-01-30 2019-11-15 学校法人日本医科大学 腺相关病毒(aav)衣壳蛋白的突变体
MX2020003779A (es) 2017-09-27 2020-08-03 Procter & Gamble Composiciones detergentes que comprenden lipasas.
CN117448299A (zh) * 2017-09-27 2024-01-26 诺维信公司 脂肪酶变体和包含此类脂肪酶变体的微囊组合物
WO2019154954A1 (en) * 2018-02-08 2019-08-15 Novozymes A/S Lipase variants and compositions thereof
CN111334369B (zh) * 2020-03-11 2022-10-21 陕西科技大学 一种酶法制备卵磷脂型pufa的方法
JP2023547450A (ja) * 2020-10-29 2023-11-10 ノボザイムス アクティーゼルスカブ リパーゼ変異体及びそのようなリパーゼ変異体を含む組成物
WO2023225459A2 (en) 2022-05-14 2023-11-23 Novozymes A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections
CN113846074B (zh) * 2021-10-20 2022-10-21 南京林业大学 一种疏棉状嗜热丝孢菌脂肪酶突变体g91c及其应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173590D0 (da) * 1990-06-06 1990-07-19 Novo Nordisk As Rekombinante terapeutiske lipaser
DK46693D0 (de) * 1993-04-23 1993-04-23 Novo Nordisk As
KR930702514A (ko) * 1990-09-13 1993-09-09 안네 제케르 리파제 변체
US5869438A (en) * 1990-09-13 1999-02-09 Novo Nordisk A/S Lipase variants
DE69130113T2 (de) 1990-12-05 1999-05-12 Novo Nordisk A/S, Bagsvaerd Proteine mit geänderten epitopen und verfahren zur deren herstellung
US5914306A (en) 1991-05-01 1999-06-22 Novo Nordisk A/S Stabilized enzymes
DK39693D0 (da) 1993-04-02 1993-04-02 Novo Nordisk As Enzym
US5866526A (en) 1993-10-04 1999-02-02 Novo Nordisk A/S Enzyme preparation comprising a modified enzyme
CN1077598C (zh) * 1994-02-22 2002-01-09 诺沃奇梅兹有限公司 制备脂解酶变异体的方法
EP0793726A1 (de) 1994-11-24 1997-09-10 Novo Nordisk A/S Verfahren zur herstellung von polypeptiden mit veringerter hervorrufung von allergien
MX9704137A (es) 1994-12-07 1997-09-30 Novo Nordisk As Polipeptidos de alergenicidad reducida.
EP0805856B2 (de) 1995-01-26 2009-04-01 Novozymes A/S Xylanase beinhaltende futterzusätze für tiere
US6495357B1 (en) * 1995-07-14 2002-12-17 Novozyme A/S Lipolytic enzymes
DE69633825T2 (de) 1995-07-14 2005-11-10 Novozymes A/S Modifiziertes enzym mit lipolytischer aktivität
EP0851913B1 (de) 1995-08-11 2004-05-19 Novozymes A/S Neuartige lipolytische enzyme
AU736806B2 (en) 1997-01-10 2001-08-02 Novozymes A/S A modified enzyme for skin care
AU740207B2 (en) 1997-02-06 2001-11-01 Novozymes A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
AU751880B2 (en) 1997-06-25 2002-08-29 Novozymes A/S A modified polypeptide
ATE328070T1 (de) * 1998-02-17 2006-06-15 Novozymes As Lipasevariante
AU3247699A (en) 1998-02-17 1999-09-06 Novo Nordisk A/S Lipase variant
CA2346929A1 (en) 1998-10-13 2000-04-20 Novozymes A/S A modified polypeptide with reduced immune response
ES2220114T3 (es) 1998-10-30 2004-12-01 Novozymes A/S Variantes de proteinas poco alergenicas.
CN1325443A (zh) 1998-10-30 2001-12-05 诺沃奇梅兹有限公司 具有减弱的变应原性的糖基化蛋白
US7312062B2 (en) * 1998-11-27 2007-12-25 Novozymes A/S Lipolytic enzyme variants
DK1131416T3 (da) 1998-11-27 2009-10-26 Novozymes As Lipolytiske enzymvarianter
JP4938174B2 (ja) 1999-03-17 2012-05-23 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病を治療するための医薬品
WO2000060063A1 (en) 1999-03-31 2000-10-12 Novozymes A/S Lipase variant
CN100455663C (zh) * 1999-03-31 2009-01-28 诺维信公司 脂肪酶变体
DK1257176T3 (da) 2000-02-08 2008-08-18 Dsm Ip Assets Bv Anvendelse af syrestabile proteaser i dyrefoder
ATE471377T1 (de) 2000-04-28 2010-07-15 Novozymes As Variante eines lipolytischen enzyms
EP1352057B1 (de) 2001-01-10 2009-03-25 Novozymes A/S Variante eines lipolytischen enzyms
AR032392A1 (es) 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
WO2002062973A2 (en) 2001-02-07 2002-08-15 Novozymes A/S Lipase variants
CA2467415C (en) * 2002-01-16 2014-03-11 Novozymes A/S Lipolytic enzyme variants and method for their production
US20060234340A1 (en) 2003-02-06 2006-10-19 Novozymes A/S Human heavy chain antibody expression in flamentous fungi
DK2270139T3 (en) * 2003-05-09 2016-11-07 Novozymes As Lipolytic Enzyme Variants
EP1639102A2 (de) * 2003-06-19 2006-03-29 Novozymes A/S Phospholipasevarianten
WO2004111224A1 (en) 2003-06-19 2004-12-23 Novozymes A/S Improved proteases and methods for producing them
WO2005070962A1 (en) 2004-01-21 2005-08-04 Novozymes A/S Production of a monoclonal antibody in a heterokaryon fungus or in a fungal host cell
BRPI0509148B8 (pt) 2004-03-22 2021-05-25 Abbott Products Gmbh composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina contendo tensoativos, seus usos e respectivos processos de fabricação
PT2198880T (pt) 2004-10-14 2017-01-04 Lilly Co Eli Composições contendo lipase, protease e amilase para o tratamento de insuficiência pancreática
US20080138856A1 (en) 2005-02-10 2008-06-12 Novozymes A/S Enzymatic Enantioselective Ester or Amide Hydrolysis or Synthesis
JP2008546396A (ja) 2005-06-24 2008-12-25 ノボザイムス アクティーゼルスカブ 薬学的に使用するためのアミラーゼ
MX2007015474A (es) 2005-06-24 2008-04-22 Novozymes As Proteasas para uso farmaceutico.
AU2006261442A1 (en) * 2005-06-24 2006-12-28 Novozymes A/S Lipases for pharmaceutical use
WO2007080197A2 (en) * 2006-01-16 2007-07-19 Novozymes A/S Immobilised enzymes
CN105296445B (zh) * 2006-01-23 2022-05-10 诺维信公司 脂肪酶变体
US7786067B2 (en) * 2006-01-23 2010-08-31 The Procter & Gamble Company Composition comprising a lipase and a bleach catalyst
CN105112386A (zh) * 2006-12-21 2015-12-02 诺维信公司 用于药物用途的脂肪酶变体

Also Published As

Publication number Publication date
ZA200903598B (en) 2010-04-28
IL198893A0 (en) 2010-02-17
US20150209414A1 (en) 2015-07-30
EP2455461A3 (de) 2013-05-29
EP2455462A2 (de) 2012-05-23
US20100034797A1 (en) 2010-02-11
CN105112386A (zh) 2015-12-02
EP2261328A1 (de) 2010-12-15
EP2455460A2 (de) 2012-05-23
EP2455459B1 (de) 2016-03-16
TW200829698A (en) 2008-07-16
CN101743308A (zh) 2010-06-16
CA2670643A1 (en) 2008-07-03
RU2009128067A (ru) 2011-01-27
US8273348B2 (en) 2012-09-25
CA3081308A1 (en) 2008-07-03
CN101743308B (zh) 2015-09-16
MX2009006597A (es) 2009-07-02
EP2455461B1 (de) 2016-03-16
WO2008079685A2 (en) 2008-07-03
EP2455460A3 (de) 2012-12-26
BRPI0721103A2 (pt) 2014-03-04
WO2008079685A3 (en) 2008-11-06
EP2455459A2 (de) 2012-05-23
AU2007337150A1 (en) 2008-07-03
AR064494A1 (es) 2009-04-08
JP5406040B2 (ja) 2014-02-05
US9539311B2 (en) 2017-01-10
KR20090101930A (ko) 2009-09-29
EP2261328B1 (de) 2013-11-20
CA3081308C (en) 2024-02-20
EP2455462A3 (de) 2013-05-29
CA2670643C (en) 2017-04-25
EP2455461A2 (de) 2012-05-23
US20120308543A1 (en) 2012-12-06
JP2010512795A (ja) 2010-04-30
CA2961041A1 (en) 2008-07-03
CA2961041C (en) 2020-07-14
EP2099907A2 (de) 2009-09-16
EP2455459A3 (de) 2013-04-24
EP2455462B1 (de) 2016-03-16
US9029115B2 (en) 2015-05-12

Similar Documents

Publication Publication Date Title
NO20092729L (no) Lipasevarianter for farmasoytisk anvendelse
NO20080437L (no) Lipaser til farmasoytisk anvendelse
McClellan et al. Cellular functions and molecular mechanisms of non-lysine ubiquitination
Draganov Lactonases with oragnophosphatase activity: structural and evolutionary perspectives
Cornaciu et al. The minimal domain of adipose triglyceride lipase (ATGL) ranges until leucine 254 and can be activated and inhibited by CGI-58 and G0S2, respectively
DK1755656T3 (da) Enzymer til farmaceutisk anvendelse
NO20080439L (no) Amylaser til farmasoytisk anvendelse
Chandrasekaran et al. In search of a catalytic bioscavenger for the prophylaxis of nerve agent toxicity
NL300874I2 (nl) Elosulfase alfa
JP2010512795A5 (de)
NO20080438L (no) Proteaser til farmasoytisk anvendelse
RU2011102781A (ru) ПРИМЕНЕНИЕ Hsp70 В КАЧЕСТВЕ РЕГУЛЯТОРА ФЕРМЕНТАТИВНОЙ АКТИВНОСТИ
DK1162995T3 (da) Enzymer til behandling af diabetes mellitus type I
EP4241854A3 (de) Enzym für die lysosomale speicherkrankheit
Parzych et al. Vacuolar hydrolysis and efflux: current knowledge and unanswered questions
EA201070187A1 (ru) Модифицированные ферменты лецитин-холестерин ацилтрансферазы
MX2010005690A (es) Variantes de proteasa para uso farmaceutico.
US11584920B2 (en) Use of enzymes with a wide pH activity range as medicaments for promoting digestion
Mandrich et al. Hyperthermophilic phosphotriesterases/lactonases for the environment and human health
Taylor et al. Cholinesterase confabs and cousins: approaching forty years
TH88730A (th) ไลเปสสำหรับการใช้ทางเภสัชกรรม
TH105721B (th) แวเรียนท์ของไลเปสสำหรับการใช้ทางเภสัชกรรม
TH105721A (th) แวเรียนท์ของไลเปสสำหรับการใช้ทางเภสัชกรรม
WO2008040739A3 (en) Lipolytic enzyme variants
Roy et al. Expression of recombinant human cathepsin K is enhanced by codon optimization

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application